Prevention of Coronary Slow Flow or No-Reflow During EPCI in Patients With Acute STEMI

Summary

Elective percutaneous coronary intervention (EPCI) is the common treatment of ST segment elevation myocardial infarction (STEMI).Slow flow / no-reflow phenomenon following EPCI in STEMI patients has been a serious and common complication that closely related to the incidence of major adverse cardiovascular events (MACE) and affected patients' prognosis. No reflow is a multi-factorial phenomenon. And its preventive and therapeutic effects are not satisfactory. This prospective randomized controlled study aimed to compare favorable effects of Nitroprusside versus Tirofiban on the prevention of slow flow / no-reflow phenomenon during EPCI.

Conditions

• ST Segment Elevation Myocardial Infarction
• Elective Percutaneous Coronary Intervention

Interventions

DRUG

Nitroprusside Sodium

Intracoronary infusion 50\~100μg each time (repeated)

DRUG

Tirofiban Hydrochloride

Intracoronary infusion 10μg/kg for single time

DRUG

Heparinized saline

Intracoronary infusion 2ml for single time

Sponsors & Collaborators

• Anyang Regional Hospital

  collaborator OTHER

• Huaihe Hospital of Henan University

  collaborator OTHER

• The First Affiliated Hospital of Henan University of Science and Technology

  collaborator OTHER

• Yellow River Sanmenxia hospital

  collaborator UNKNOWN

• The Peoples' Hospital of Jiaozuo City

  collaborator OTHER

• Jincheng People's Hospital

  collaborator OTHER

• The second people's Hospital of Jiyuan

  collaborator UNKNOWN

• Kaifeng Central Hospital

  collaborator OTHER

• Lushan People's Hospital

  collaborator UNKNOWN

• Nanyang Central Hospital

  collaborator OTHER

• The Second People's Hospital of Pingdingshan

  collaborator UNKNOWN

• Shenma Medical Group General Hospital

  collaborator OTHER

• Puyang People's Hospital

  collaborator UNKNOWN

• Puyang Oilfield General Hospital

  collaborator OTHER

• The First People's Hospital of Shangqiu

  collaborator UNKNOWN

• Yanshi People's Hospital

  collaborator UNKNOWN

• The First People's Hospital of Xinmi

  collaborator UNKNOWN

• First Affiliated Hospital of Xinjiang Medical University

  collaborator OTHER

• Xinyang Central Hospital

  collaborator OTHER

• People's Hospital of Zhengzhou University

  collaborator OTHER

• Zhengzhou First People's Hospital

  collaborator UNKNOWN

• Chinese Academy of Medical Sciences, Fuwai Hospital

  collaborator OTHER

• Zhengzhou Central Hospital

  collaborator OTHER

• The 99th Central Hospital of the People's Liberation Army

  collaborator UNKNOWN

• Zhoukou Central Hospital

  collaborator OTHER

• The First People's Hospital of Zhumadian

  collaborator UNKNOWN

• Zhumadian Central Hospital

  collaborator OTHER

• The First Affiliated Hospital of Zhengzhou University

  lead OTHER

Principal Investigators

• Chunguang Qiu, Phd · The First Affiliated Hospital of Zhengzhou University

Study Design

Allocation

RANDOMIZED

Purpose

PREVENTION

Masking

SINGLE

Model

PARALLEL

Eligibility

Min Age

18 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2018-01-08

Primary Completion

2019-06-30

Completion

2019-12-31

Countries

• China

Study Locations